NCT06610305View on ClinicalTrials.gov

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2026

Conditions

Major Depressive Disorder

Interventions

DRUG

Transdermal estradiol

0.1 mg/day delivered via weekly patch

DRUG

Progesterone

100 mg twice daily (200 mg/day total) administered via oral capsule

DRUG

Transdermal placebo patch

Once weekly via transdermal patch

DRUG

placebo capsule

Twice daily via oral capsule

Trial Locations (1)

27707

RECRUITING

University of North Carolina, Chapel Hill, Chapel Hill

All Listed Sponsors

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT06610305 - Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression | Biotech Hunter | Biotech Hunter